LCM
IBIO icon

Lynx1 Capital Management’s iBio IBIO Stock Holding History

Lynx1 Capital Management’s Portfolio IBIO Stock Details IBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-68,076
Closed -$129K – 29
2026
Q1 		$129K Buy
+68,076
New +$158K 0.02% 19
2025
Q4 		– Sell
-1,055,897
Closed -$874K – 25
2025
Q3 		$874K Sell
1,055,897
-482,676
-31% -$371K 0.18% 12
2025
Q2 		$1.17M Buy
1,538,573
+676,294
+78% +$734K 0.34% 12
2025
Q1 		$3.47M Hold
862,279
– – 1.24% 10
2024
Q4 		$2.11M Hold
862,279
– – 0.79% 13
2024
Q3 		$1.91M Buy
862,279
+21,516
+3% +$42.5K 0.68% 9
2024
Q2 		$1.77M Buy
840,763
+240,763
+40% +$518K 0.64% 11
2024
Q1 		$2.44M Buy
+600,000
New +$754K 0.63% 12

Other funds holding IBIO

AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.95B AUM 773.9% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $60.8B AUM 42.06% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Lynx1 Capital Management's IBIO Position: Q2 2026 in Review

Lynx1 Capital Management sold out of iBio (IBIO) in Q2 2026, closing a stake of 68,076 shares — an estimated $129K sold.

Lynx1 Capital Management first reported a position in IBIO in Q1 2024 and held it in 8 quarters. The position peaked at $3.47M in Q1 2025. 55 funds tracked by Wall St. Rank hold IBIO as of Q2 2026.

  • Lynx1 Capital Management reported no remaining iBio position as of Q2 2026 after selling out during the quarter.
  • Lynx1 Capital Management sold 68,076 iBio shares in Q2 2026, an estimated $129K.
  • Lynx1 Capital Management first reported a position in iBio in Q1 2024 and held it in 8 quarters.
  • Lynx1 Capital Management's iBio position peaked at $3.47M in Q1 2025.
  • 55 funds tracked by Wall St. Rank held iBio as of Q2 2026.

Based on Lynx1 Capital Management's 13F filing for Q2 2026, filed 12 Aug 2026.